2025, Vol. 5, Issue 1, Part A

Author(s)
Amina Bello

Abstract
Negative symptoms in schizophrenia-such as apathy, anhedonia, alogia, avolition, and affective flattening-pose significant challenges to treatment and functional recovery. While positive symptoms are often well-managed with antipsychotics, negative symptoms remain persistently debilitating. Clozapine, a second-generation antipsychotic known for its efficacy in treatment-resistant schizophrenia, has demonstrated some promise in reducing negative symptoms, though not without substantial side effects. Aripiprazole, a newer atypical antipsychotic with partial dopamine agonist activity, offers a distinct pharmacological approach and potentially favorable tolerability. This paper aims to critically compare the efficacy of Clozapine and Aripiprazole in reducing negative symptoms based on clinical trials, meta-analyses, and pharmacological evidence. It also explores neurobiological mechanisms, patient outcomes, and real-world effectiveness. The analysis reveals that while Clozapine remains superior in severe, resistant cases, Aripiprazole provides a safer profile with moderate effectiveness, suggesting their roles may be complementary depending on clinical context. The findings underscore the need for more targeted therapies addressing negative symptoms specifically.

DOI: https://doi.org/10.22271/27891623.2025.v5.i1a.68

Pages: 28-32 | Views: 65 | Downloads: 22